Westphal D, Garzarolli M, Sergon M, Horak P, et al. High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinoma. Br J Dermatol 2021;185:1186-1199.
PMID: 34185311